» Articles » PMID: 35933467

Integrative Profiling of Amyotrophic Lateral Sclerosis Lymphoblasts Identifies Unique Metabolic and Mitochondrial Disease Fingerprints

Overview
Journal Mol Neurobiol
Date 2022 Aug 6
PMID 35933467
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with a rapid progression and no effective treatment. Metabolic and mitochondrial alterations in peripheral tissues of ALS patients may present diagnostic and therapeutic interest. We aimed to identify mitochondrial fingerprints in lymphoblast from ALS patients harboring SOD1 mutations (mutSOD1) or with unidentified mutations (undSOD1), compared with age-/sex-matched controls. Three groups of lymphoblasts, from mutSOD1 or undSOD1 ALS patients and age-/sex-matched controls, were obtained from Coriell Biobank and divided into 3 age-/sex-matched cohorts. Mitochondria-associated metabolic pathways were analyzed using Seahorse MitoStress and ATP Rate assays, complemented with metabolic phenotype microarrays, metabolite levels, gene expression, and protein expression and activity. Pooled (all cohorts) and paired (intra-cohort) analyses were performed by using bioinformatic tools, and the features with higher information gain values were selected and used for principal component analysis and Naïve Bayes classification. Considering the group as a target, the features that contributed to better segregation of control, undSOD1, and mutSOD1 were found to be the protein levels of Tfam and glycolytic ATP production rate. Metabolic phenotypic profiles in lymphoblasts from ALS patients with mutSOD1 and undSOD1 revealed unique age-dependent different substrate oxidation profiles. For most parameters, different patterns of variation in experimental endpoints in lymphoblasts were found between cohorts, which may be due to the age or sex of the donor. In the present work, we investigated several metabolic and mitochondrial hallmarks in lymphoblasts from each donor, and although a high heterogeneity of results was found, we identified specific metabolic and mitochondrial fingerprints, especially protein levels of Tfam and glycolytic ATP production rate, that may have a diagnostic and therapeutic interest.

Citing Articles

Characterization of the Mitochondria Function and Metabolism in Skin Fibroblasts Using the Biolog MitoPlate S-1.

de Lemos A, Teixeira J, Cunha-Oliveira T Methods Mol Biol. 2024; 2878():75-98.

PMID: 39546258 DOI: 10.1007/978-1-0716-4264-1_5.


Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis.

Cunha-Oliveira T, Montezinho L, Simoes R, Carvalho M, Ferreiro E, Silva F Cells. 2024; 13(3.

PMID: 38334639 PMC: 10854804. DOI: 10.3390/cells13030248.


Metabolic Priming as a Tool in Redox and Mitochondrial Theragnostics.

Pinho S, Anjo S, Cunha-Oliveira T Antioxidants (Basel). 2023; 12(5).

PMID: 37237939 PMC: 10215850. DOI: 10.3390/antiox12051072.


Amyotrophic Lateral Sclerosis Pathoetiology and Pathophysiology: Roles of Astrocytes, Gut Microbiome, and Muscle Interactions via the Mitochondrial Melatonergic Pathway, with Disruption by Glyphosate-Based Herbicides.

Anderson G Int J Mol Sci. 2023; 24(1).

PMID: 36614029 PMC: 9820185. DOI: 10.3390/ijms24010587.

References
1.
Longinetti E, Fang F . Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019; 32(5):771-776. PMC: 6735526. DOI: 10.1097/WCO.0000000000000730. View

2.
Dhasmana S, Dhasmana A, Narula A, Jaggi M, Yallapu M, Chauhan S . The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sci. 2021; 288:120156. DOI: 10.1016/j.lfs.2021.120156. View

3.
Wijesekera L, Leigh P . Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4:3. PMC: 2656493. DOI: 10.1186/1750-1172-4-3. View

4.
Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Fernandez Altamirano P . A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015; 6:171. PMC: 4653353. DOI: 10.4103/2152-7806.169561. View

5.
Andrews J, Jackson C, Heiman-Patterson T, Bettica P, Brooks B, Pioro E . Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21(7-8):509-518. DOI: 10.1080/21678421.2020.1771734. View